artiCure and TFBS Bioscience Join Forces in Virus Manufacturing to Advance Development of Innovative Cancer Gene Therapy

Daejeon, Korea and Taipei, Taiwan — 28, August 2025 —Korea’s innovative cancer therapy company artiCure and leading viral vector manufacturer from Taiwan, TFBS Bioscience Inc. jointly announce the collaboration on GMP manufacturing of retroviral vectors, aiming to accelerate clinical trials of cancer gene therapy in Korea.

Treating cancer often requires combination therapies to overcome tumor resistance mechanisms. artiCure’s retroviral technology provides an ideal multimodal cancer gene therapy platform capable of delivering multiple therapeutic genes throughout the tumor tissue. This platform offers potent advantages for gene delivery efficiency, safety, and tolerability.

TFBS Bioscience is the first and currently only company offering GMP-grade viral vector CDMO services in Taiwan, along with GMP/GLP-compliant testing CRO services. Its service portfolio covers biopharmaceuticals and gene therapies, providing one-stop-shop solutions from process development to manufacturing and testing.

This collaboration integrates artiCure’s expertise in innovative retroviral therapy development with TFBS Bioscience’s comprehensive viral vector manufacturing and testing capabilities and experience, representing a pioneering milestone in Korea-Taiwan cooperation in the gene therapy industry.

Dr. Yeon-Soo Kim, CEO of artiCure, stated:
This collaboration with TFBS Bioscience is a major step forward in realizing artiCure’s mission to deliver advanced gene therapies for patients with hard-to-treat cancers. TFBS brings world-class viral vector manufacturing and testing capabilities, which will accelerate our transition from bench to bedside. We are proud to work with such a trusted partner and excited to contribute to a growing ecosystem of gene therapy innovation in Asia.”

Dr. Tatung Yuan, Chairman and CEO of TFBS Bioscience, commented:
“Viral vectors are a core component of gene therapy. We are honored to partner with artiCure to advance retrovirus-based gene therapies for cancer and contribute to innovation in healthcare. This collaboration also represents a significant milestone for TFBS Bioscience, combining our GMP manufacturing experience with a cutting-edge drug developer in Korea.”

This partnership highlights the success of collaboration in gene therapy between Korea and Taiwan, both parties contributing either leading R&D know how or manufacturing capabilities to achieve the gene therapy development for cancer treatment. It also indicates the importance of geographical collaboration for the development of cell and gene therapy products in Asia.

About artiCure

artiCure is a Korea-based biotech company dedicated to developing multimodal gene therapies that overcome the limitations of conventional cancer treatments. Its proprietary retroviral vector platform enables the tumor-selective delivery of multiple therapeutic genes, offering synergistic effects against solid tumors and minimal systemic toxicity. With strong translational capabilities and a commitment to clinical advancement, artiCure is driving the next generation of cancer gene therapy innovation. To learn more, please visit www.articure.kr.

About TFBS Bioscience Inc.

TFBS Bioscience Inc. (TFBS) is Taiwan’s first viral vector contract development and manufacturing organization (CDMO), providing fully integrated end-to-end services for adeno-associated virus, lentivirus, and retrovirus. With its state-of-the-art facility and customization expertise, TFBS offers a one-stop-shop solution for gene and cell therapy, supporting clients from clinical trials to GMP commercial production. Founded in 2016 as a contract research organization (CRO) providing GLP biological testing, TFBS has also built a strong track record in regulatory submissions, earning trust from international regulatory agencies and the biopharmaceutical industry.

For more information, please visit www.tfbsbio.com.